The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Palbociclib, Ribociclib and Abemaciclib for HR-Positive Breast Cancer: CDK4/6 Inhibitor Therapy

Cell cycle inhibitors transforming hormone receptor-positive metastatic and adjuvant breast cancer treatment

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Palbociclib, Ribociclib and Abemaciclib for HR-Positive Breast Cancer: CDK4/6 Inhibitor Therapy?

CDK4/6 inhibitors block cyclin-dependent kinase phosphorylation of retinoblastoma protein preventing cell cycle progression.

Palbociclib (Ibrance) was first FDA-approved CDK4/6 inhibitor in 2015 with subsequent ribociclib and abemaciclib approvals.

Combination with aromatase inhibitor as first-line therapy for postmenopausal women or fulvestrant in subsequent settings demonstrated efficacy.

MONARCH-E trial established adjuvant abemaciclib for high-risk early HR-positive breast cancer reducing recurrence risk.

Mechanism includes both anti-proliferative effects and induction of senescence and immune microenvironment modulation.

Symptoms

Neutropenia is most common adverse effect with palbociclib and ribociclib though febrile neutropenia rate is low.
Diarrhea is more prominent with abemaciclib than palbociclib or ribociclib requiring loperamide management.
QTc prolongation specifically with ribociclib requires baseline ECG and serial monitoring.
Hepatotoxicity may occur with all three agents requiring liver function monitoring.
Interstitial lung disease and pneumonitis are rare but serious adverse events requiring respiratory symptom monitoring.

Risk Factors

Pre-existing neutropenia or marrow reserve issues affect tolerability requiring dose modification considerations.
Cardiac conditions including QTc prolongation history affect ribociclib selection and monitoring requirements.
Pre-existing diarrhea or inflammatory bowel disease may worsen with abemaciclib particularly.
Drug interactions with strong CYP3A4 inhibitors and inducers require careful concomitant medication review.
Hepatic impairment requires dose modification per established criteria for each agent.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Newly diagnosed metastatic HR-positive HER2-negative breast cancer warrants CDK4/6 inhibitor consideration with endocrine therapy.
  • Adjuvant therapy for high-risk early HR-positive breast cancer warrants abemaciclib consideration per MONARCH-E criteria.
  • Severe neutropenia, fever or infection during treatment requires evaluation and dose modification.
  • Severe diarrhea, dehydration or electrolyte abnormalities warrant prompt medical attention.
  • New respiratory symptoms during treatment require evaluation excluding pneumonitis.

Treatment Methods

01
Palbociclib 125 mg daily 21 days on/7 days off cycle combined with aromatase inhibitor or fulvestrant.
02
Ribociclib 600 mg daily 21 days on/7 days off cycle with aromatase inhibitor or fulvestrant in metastatic setting.
03
Abemaciclib 150 mg twice daily continuous dosing combined with endocrine therapy in metastatic or adjuvant setting.
04
Comprehensive monitoring including complete blood count, liver function, ECG for ribociclib and patient-reported symptoms.
05
Multidisciplinary care including medical oncology, breast surgery, supportive care and patient education optimizes outcomes through these transformative agents that have substantially improved hormone receptor-positive breast cancer survival.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.